Daniel Paul Regan, Chief Commercial Officer at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 8,124 shares at $341.21 ($2.6M) on 2014-08-12, disclosed to the SEC on 2014-08-15.
Scheduled sale ($2.6M) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $305.39 | 200 | $61K | 2.3% |
| 2 | $306.91 | 100 | $31K | 1.2% |
| 3 | $310.10 | 500 | $155K | 5.9% |
| 4 | $311.89 | 500 | $156K | 5.9% |
| 5 | $312.78 | 200 | $63K | 2.4% |
| 6 | $313.84 | 800 |
| $251K |
| 9.5% |
| 7 | $314.93 | 600 | $189K | 7.1% |
| 8 | $316.62 | 200 | $63K | 2.4% |
| 9 | $317.71 | 400 | $127K | 4.8% |
| 10 | $319.47 | 400 | $128K | 4.8% |
| 11 | $321.44 | 200 | $64K | 2.4% |
| 12 | $322.92 | 100 | $32K | 1.2% |
| 13 | $326.03 | 100 | $33K | 1.2% |
| 14 | $327.89 | 300 | $98K | 3.7% |
| 15 | $329.59 | 594 | $196K | 7.4% |
| 16 | $330.91 | 206 | $68K | 2.6% |
| 17 | $331.92 | 200 | $66K | 2.5% |
| 18 | $335.02 | 100 | $34K | 1.3% |
| 19 | $336.47 | 200 | $67K | 2.5% |
| 20 | $337.17 | 100 | $34K | 1.3% |
| 21 | $341.21 | 300 | $102K | 3.9% |
| 22 | $342.05 | 300 | $103K | 3.9% |
| 23 | $343.80 | 800 | $275K | 10.4% |
| 24 | $344.73 | 500 | $172K | 6.5% |
| 25 | $346.68 | 224 | $78K | 2.9% |
| Total | $325.70 avg | 8,124 | $2.6M | 100% |
| Filing → |
| ICPT | SELL | 2014-07-08 | $250 | — | Filing → |
| ICPT | SELL | 2014-03-07 | $8.7M | — | Filing → |